Home
Company
Product
Regulation
China
Data
Exhibition
Interview
中文版
Home
Company
Product
Regulation
China
Data
Exhibition
Interview
中文版
Search

Qnovia Initiates First Phase of RespiRx™ Nicotine Inhaler Trial

Jan.13.2025
Qnovia Initiates First Phase of RespiRx™ Nicotine Inhaler Trial
Qnovia, Inc. announces the first patient dosed in the US clinical trial of RespiRx™ Nicotine Inhaler for smoking cessation.

According to PR Newswire's report on January 7th, the US pharmaceutical company Qnovia, Inc. announced that the first patient in the US has been administered with RespiRx™ nicotine inhaler (QN-01) in the phase I clinical trial as a smoking cessation therapy.


RespiRx™ is a drug delivery device that combines a portable handheld nebulizer with a metered dose medication cartridge to administer medication in aerosol form.


Qnovia's CEO Brian Quigley stated,


We are pleased to have administered medication to the first patient in our first clinical trial, aimed at addressing global cigarette use issues and innovating smoking cessation treatment. Overall, we believe today's news represents Qnovia's official transformation into a biopharmaceutical company, developing the next generation of smoking cessation therapies.


This clinical trial aims to address the need for effective and easily accessible smoking cessation therapy, evaluating the pharmacokinetics, safety, and tolerability of RespiRx™. The trial is a randomized crossover open-label study, including up to 24 healthy adult smokers. The primary endpoints are the maximum concentration, AUC 0-30, and Tmax of plasma nicotine after baseline adjustment. The study is being conducted by Vince Clinical Research Company in Overland Park.


The company expects to release the first phase trial data of the RespiRx™ nicotine inhaler in the second quarter of 2025, and submit a clinical trial application in the UK in the second half of 2025.


Qnovia, Inc. is a US-based platform medical technology and pharmaceutical company founded by Mario Danek in 2018. It focuses on developing and commercializing proprietary inhalation device technology to improve patient outcomes. Its flagship product, RespiRx™, is a medication-grade inhalation drug delivery system based on a cartridge, designed to help smokers quit smoking.


References:
[1] Qnovia, Inc. Announces First Patient Dosed in U.S. in Phase 1 study for RespiRx™ Nicotine Inhaler as a prescription smoking cessation therapy
Also Read:
[1] Qnovia Announces Promising Results of Inhalation Smoking Cessation Therapy
#North America#United States#Technology.#Nicotine inhaler

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn

Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

China Tobacco Regulation Shift：Policy Updates and Market Impact
China Tobacco Regulation Shift：Policy Updates and Market Impact
FDA Rolls Out Online PMTA Platform, a Move That 2Firsts Analysts Say Could Pull Grey-Market Products Toward Formal Compliance
FDA Rolls Out Online PMTA Platform, a Move That 2Firsts Analysts Say Could Pull Grey-Market Products Toward Formal Compliance
FDA’s launch of a web-based PMTA system signals faster reviews and, 2Firsts experts say, a possible inflection point for the U.S. e-cigarette market’s shift out of the grey zone.
Dec.04
Lancet Study Finds Rising Use of Nicotine Pouches in Britain
Lancet Study Finds Rising Use of Nicotine Pouches in Britain
A study published in The Lancet has found that nicotine pouch use is increasing in Britain, particularly among young men. Usage among people aged 16 to 24 has risen sharply since early 2022.
Dec.17 by 2FIRSTS.ai
EU to Abstain from WHO Tobacco Treaty Vote Amid Deep Internal Split
EU to Abstain from WHO Tobacco Treaty Vote Amid Deep Internal Split
The European Union will abstain from voting at the upcoming 11th session of the WHO Framework Convention on Tobacco Control (COP11) in Geneva, following months of internal disagreement over how to regulate tobacco and nicotine products. The decision marks a rare and public fracture in EU health policy, reportedly driven by the European Commission’s hardline anti-tobacco stance.
Nov.18 by 2FIRSTS.ai
China’s E-Cigarette Exports USD 1.096 billion in November, UK and South Korea Offset U.S. Decline
China’s E-Cigarette Exports USD 1.096 billion in November, UK and South Korea Offset U.S. Decline
China’s e-cigarette exports edged lower in November 2025, totaling USD 1.096 billion, down 0.2% month-on-month, as a decline in shipments to the United States was partially offset by stronger demand from the United Kingdom, Germany and South Korea, according to data released by the General Administration of Customs of China.
Dec.22 by 2FIRSTS.ai
Congress Calls on FDA to Allocate at Least $200 Million for ENDS Enforcement, Multi-Agency Task Force to Target Illegal e-Cigarette Imports. IKE Tech and Ispire Utilize Blockchain and Age Verification Technology to Support Regulation, Submit Chips as Part
Congress Calls on FDA to Allocate at Least $200 Million for ENDS Enforcement, Multi-Agency Task Force to Target Illegal e-Cigarette Imports. IKE Tech and Ispire Utilize Blockchain and Age Verification Technology to Support Regulation, Submit Chips as Part
Congress demands FDA allocate at least $200 million for ENDS enforcement; multi-agency task force to combat illegal e-cigarette imports.
Nov.18 by 2FIRSTS.ai
Sweden on Track to Become Europe’s First Smoke-Free Nation as Snus and Nicotine Pouches Support Declining Smoking Rates
Sweden on Track to Become Europe’s First Smoke-Free Nation as Snus and Nicotine Pouches Support Declining Smoking Rates
According to Gulf News, Sweden is nearing the World Health Organization’s smoke-free threshold, with daily smoking falling below 5%. Two decades of public health efforts and the growing use of lower-risk alternatives such as Snus and tobacco-free nicotine pouches have contributed to this shift, alongside declines in tobacco-related deaths and lung cancer cases.
Dec.04 by 2FIRSTS.ai
Related Topics
News Company
Related Read
FDA Rolls Out Online PMTA Platform, a Move That 2Firsts Analysts Say Could Pull Grey-Market Products Toward Formal Compliance
FDA Rolls Out Online PMTA Platform, a Move That 2Firsts Analysts Say Could Pull Grey-Market Products Toward Formal Compliance
Lancet Study Finds Rising Use of Nicotine Pouches in Britain
Lancet Study Finds Rising Use of Nicotine Pouches in Britain
2FIRSTS.ai
EU to Abstain from WHO Tobacco Treaty Vote Amid Deep Internal Split
EU to Abstain from WHO Tobacco Treaty Vote Amid Deep Internal Split
2FIRSTS.ai
China’s E-Cigarette Exports USD 1.096 billion in November, UK and South Korea Offset U.S. Decline
China’s E-Cigarette Exports USD 1.096 billion in November, UK and South Korea Offset U.S. Decline
2FIRSTS.ai
Congress Calls on FDA to Allocate at Least $200 Million for ENDS Enforcement, Multi-Agency Task Force to Target Illegal e-Cigarette Imports. IKE Tech and Ispire Utilize Blockchain and Age Verification Technology to Support Regulation, Submit Chips as Part
Congress Calls on FDA to Allocate at Least $200 Million for ENDS Enforcement, Multi-Agency Task Force to Target Illegal e-Cigarette Imports. IKE Tech and Ispire Utilize Blockchain and Age Verification Technology to Support Regulation, Submit Chips as Part
2FIRSTS.ai
Sweden on Track to Become Europe’s First Smoke-Free Nation as Snus and Nicotine Pouches Support Declining Smoking Rates
Sweden on Track to Become Europe’s First Smoke-Free Nation as Snus and Nicotine Pouches Support Declining Smoking Rates
2FIRSTS.ai
FOLLOW US ON SOCIAL MEDIA
Contact: info@2firsts.com
Stay up to date.
Submit your email to receive weekly newsletter on the most relevant news of the e-cigarette industry.
© 2026 Shenzhen 2FIRSTS Technology Co.,Ltd. All Right Reserved.
2FIRSTS is only accessible to industry practitioners, researchers, media and other professionals. Access by minors is prohibited.
This website provides services to users outside the Chinese mainland. For Chinese mainland users, please visit https://cn.2firsts.com
English
English
中文